Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Udine
Clinical trial register · Italy

Clinical Trials in Udine, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6791 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:19 UTC
6791
Studies in scope
all four open statuses
4079
Recruiting now
open to new participants
1019
Lead sponsors
across recruiting studies
Top sites
Milan 2846 Bologna 1303 Roma 1272 Naples 983 Rome 968
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Udine5 Merck Sharp & Dohme LLC4 Bristol-Myers Squibb4 Janssen Research & Development, LLC4 Novo Nordisk A/S4
Site location
Milan2846 Bologna1303 Roma1272 Naples983 Rome968
All 489 locations
Target enrolment
to

Trials with a site in Udine

123 of 6791 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
158
Brescia, Milan, Roma, Udine
2026-11
Not yet open
Effect of KA-EX Supplementation on Recovery Parameters in High-Level Young Football Players
NCT07824752Sport, Muscle Fatigue, Recovery of Function (G11.427.698.620), Athletic Performance
Antonio Molina Lopez
Not applicable
25
Udine
2026-09-05
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Bari, Bologna, Foggia, Messina, Milan, Roma, Udine
2026-08-05
Recruiting
Ipsen
Observational
30
Florence, Naples, Padova, Roma, Torino, Udine
2026-07-10
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Chieti, Cosenza, Naples, Bentivoglio, Bologna, Ferrara, Reggio Emilia, Udine
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
Bologna, Milan, Roma, Udine
2026-05-11
Not yet open
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
NCT07463781Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)
Fondazione Italiana Linfomi - ETS
Observational
100
Alessandria, Ancona, Brescia, Palermo, Reggio Calabria, Roma, Taranto, Udine
2026-05
Recruiting
Novo Nordisk A/S
Phase 3
400
Udine, Rome, Milan, San Donato Milanese, Verona
2026-04-20
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Udine
2026-04-15
Recruiting
Novo Nordisk A/S
Phase 3
400
Naples, Modena, Udine, Rome, Milan, San Donato Milanese, Verona
2026-04-13
Recruiting
Casa di Cura Dott. Pederzoli
Observational
200
Bologna, Padova, Roma, Trieste, Udine, Peschiera del Garda
2026-04
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
Florence, Genoa, Milan, Padua, Udine, Varese
2026-03-25
Recruiting
Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment
NCT07481539Bacteria Infection, Piperacillin, Tazobactam Drug Combination
Azienda Sanitaria Universitaria Friuli Centrale
Phase 2
240
Udine
2026-03-24
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Ancona, Catania, Milan, Perugia, Roma, Rozzano, Torino, Udine
2026-03-05
Recruiting
Casa di Cura Dott. Pederzoli
Observational
64
Naples, Abano Terme, Udine, Peschiera del Garda
2026-02-17
Active, closed
University of Udine
Not applicable
74
Udine
2025-12-01
Recruiting
iOnctura
Phase 1/2
26
Florence, Rozzano, Bologna, Meldola, Udine
2025-11-17
Recruiting
University of Bari
Not applicable
124
Bari, Udine
2025-10-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Bolzano, Modena, Meldola, Udine, Rome, Bergamo, Rozzano, Statte
2025-10-08
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
310
Parma, Bologna, Cuneo, Milan, Udine
2025-10-07
Active, closed
Bristol-Myers Squibb
Phase 2
76
Meldola, Udine, Bergamo, Florence, Novara
2025-09-19
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Bergamo, Brescia, Genova, Milan, Naples, Roma, Sanatorio San Luigi, Udine
2025-09-10
Recruiting
Association for Innovation and Biomedical Research on Light and Image
Phase 4
120
Milan, Novara, Roma, San Raffaele, Udine
2025-08-06
Recruiting
CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome
NCT07468461Camptodactyly, Arthropathy, Coxa Vara, Pericarditis
Meyer Children's Hospital IRCCS
Observational
15
Bari, Florence, Genova, Milan, Padova, Roma, Udine
2025-08-01
Recruiting
HOPE Against Cancer Recurrence in HCC
NCT06717919Liver Transplantation, HCC, Oncological Outcomes
Philipp Dutkowski
Phase 4
220
Milan, Padova, Rome, Udine
2025-08-01
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Florence, Genoa, Milan, Padua, Turin, Udine, Varese
2025-07-25
Recruiting
AstraZeneca
Phase 2
100
Florence, Milan, Modena, Pisa, Rozzano, Udine, Vicenza
2025-07-17
Recruiting
GlaxoSmithKline
Phase 2
80
Udine, Catania, Florence, Milan, Orbassano to, Rozzano MI
2025-06-05
Recruiting
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
NCT07348263Eosinophilic Fasciitis
Meyer Children's Hospital IRCCS
Observational
20
Florence, Genova, Udine
2025-05-15
Recruiting
The FOCUS-ADHF Registry
NCT06726109Acute Heart Failure With Reduced Ejection Fraction, Decompensation; Heart, Congestive, Regurgitation, Mitral
ASL Città di Torino
Observational
600
Rivoli, Turin, Udine
2025-04-27
Recruiting
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299Recurrent Pericarditis
Cardiol Therapeutics Inc.
Phase 3
110
Milan, Padua, Torino, Udine
2025-04-07
Not yet open
IRCCS Burlo Garofolo
Observational
100
Reggio Emilia, Trieste, Udine
2025-04-01
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Milan, Rozzano, Turin, Bologna, Genova, Udine
2025-03-12
Recruiting
National Cancer Institute, Naples
Phase 2
130
Caserta, Naples, Avellino, Udine, Tricase, Frattamaggiore, Pozzuoli
2025-03-12
Recruiting
University of Milano Bicocca
Phase 2
118
Avezzano, Florence, Messina, Monza, Roma, Udine
2025-03-01
Recruiting
Amgen
Phase 3
844
Udine, Rome, Milan, Turin, Verona, Pisa, Reggio Emilia
2025-02-25
Recruiting
GlaxoSmithKline
Phase 2
120
Milan, Roma, Udine
2025-02-18
Active, closed
AbbVie
Phase 3
468
Florence, Milan, Naples, Rome, Latina, Pavia, Perugia, Udine
2025-02-10
Recruiting
Università Vita-Salute San Raffaele
Not applicable
400
Catanzaro, Florence, Genova, Milan, Monza, Naples, Padova, Udine
2025-01-30
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
136
Legnano, Ravenna, Udine
2025-01-14
Recruiting
Azienda Sanitaria-Universitaria Integrata di Udine
Not applicable
80
Udine
2025-01-08
Recruiting
Istituto Oncologico Veneto IRCCS
Not applicable
200
Bergamo, Bologna, Foggia, Padova, Palermo, Udine, Verona
2024-12-20
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Candiolo, Catania, Florence, Milan, Padova, Pisa, Rozzano, Udine
2024-12-12
Recruiting
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
NCT06689956FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
Mayo Clinic
Observational
212
Verduno, Monza, Milan, Roma, Udine, Naples
2024-12-04
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Milan, Palermo, Perugia, Pisa, Roma, Rozzano, Udine
2024-12-04
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Caserta, Cremona, Naples, Rozzano, San Giovanni Rotondo, Torrette, Udine
2024-11-22
By invitation
PRObiotics for KIdney Transplantation
NCT06825117Urinary Tract Infections, Kidney Transplant Rejection, Kidney Transplant Infection, Dysbiosis
University Hospital, Udine, Italy
Not applicable
132
Udine
2024-11-15
Recruiting
University of Udine
Observational
200
Udine
2024-10-01
Active, closed
AstraZeneca
Phase 2
194
Genoa, Meldola, Milan, Naples, Orbassano, Perugia, Rozzano, Udine
2024-08-27
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
Bologna, Florence, Milan, Roma, Rome, Udine
2024-08-07
Recruiting
Centro di Riferimento Oncologico - Aviano
Not applicable
25
Aviano, Udine
2024-08-01
Active, closed
Stealth BioTherapeutics Inc.
Phase 3
313
Milan, Roma, Udine
2024-05-30
Recruiting
Lorenza Driul
Observational
200
Udine
2024-05-09
Active, closed
Erasca, Inc.
Phase 3
78
Milan, Roma, Udine
2024-04-29
Recruiting
University of Udine
Observational
90
Udine
2024-04-22
Active, closed
Amgen
Phase 3
434
Reggio Emilia, Udine, Rome, Milan, Novara, Florence, Verona, Catania
2024-04-08
Recruiting
Italfarmaco
Phase 3
220
Bari, Reggio Calabria, Bologna, Meldola, Reggio Emilia, Udine, Rome, Bergamo
2024-03-26
Recruiting
Amicus Therapeutics
Observational
500
Bari, Naples, Torino, Udine
2024-02-16
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
100
Bologna, Udine, Varese
2024-02-12
Recruiting
Amryt Pharma
Phase 4
12
Bologna, Catanzaro, Novara, Pisa, Udine
2024-02-08
Active, closed
Astellas Gene Therapies
Not applicable
119
Florence, Gussago, Messina, Milan, Pavia, Pisa, Roma, Udine
2024-02-01
Recruiting
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
89
Milan, Padova, Ravenna, Rozzano, Udine
2024-01-22
Recruiting
Tumor Microenvironment in Ovarian Cancer
NCT06272240Ovarian Cancer Stage III, Ovarian Cancer Stage IV
University of Udine
Observational
50
Udine
2024-01-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Bari, Meldola, Udine, Milan, Bergamo, Catanzaro, Florence, Roma
2023-12-15
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Brindisi, Avellino, Naples, Bologna, Meldola, Parma, Aviano (PN), Udine
2023-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Bari, Aviano, Udine, Milan, Naples, Perugia, Catania, Cuneo
2023-12-06
Active, closed
424 General Military Hospital
Observational
122
Milan, Roma, Siena, Udine
2023-11-28
Recruiting
424 General Military Hospital
Observational
150
Milan, Roma, Siena, Udine
2023-11-25
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Avellino, Bologna, Meldola, Modena, Reggio Emilia, Udine, Rome, Milan
2023-11-16
Recruiting
Centro di Riferimento Oncologico - Aviano
Observational
164
Aviano, Padova, Udine
2023-11-16
Recruiting
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06158698Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure
DrugColchicine
Niguarda Hospital
Phase 3
80
Naples, Bologna, Trieste, Udine, Rome, Milan, Turin, Ancona
2023-11-14
Active, closed
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565Hepatocellular Carcinoma
Boston Scientific Corporation
Phase 2
100
Milan, Roma, Udine
2023-11-03
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Bologna, Brescia, Milan, Pavia, Roma, Udine
2023-10-23
By invitation
Denali Therapeutics Inc.
Phase 2/3
99
Cremona, Udine
2023-09-20
By invitation
argenx
Phase 3
240
Bari, Milan, Pisa, Roma, Rozzano, Udine
2023-09-12
Active, closed
Bristol-Myers Squibb
Phase 3
774
Brescia, Milan, Naples, Pisa, Rome, Udine
2023-09-11
Recruiting
The Supplementation Therapy in Autism and Response to Treatment Study
NCT06187090Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Asperger Syndrome
University of Udine
Not applicable
20
Udine
2023-09-01
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Milan, Padova, Palermo, Roma, Rozzano, Udine
2023-04-14
Active, closed
Alfasigma S.p.A.
Phase 3
495
Bologna, Naples, Palermo, Rome, Udine
2023-04-05
Recruiting
FDG-PET in the Diagnosis of Autoimmune Encephalitis
NCT06019975Autoimmune Encephalitis
University of Milano Bicocca
Observational
90
Udine, Genoa, Pavia, Milan, Monza
2023-03-01
Active, closed
AstraZeneca
Observational
551
Naples, Cona, Udine, Rome, Brescia, Milan, Turin, Cagliari
2023-02-27
Active, closed
Cenobamate in Adults With Focal-Onset Seizures
NCT05859854Epilepsy, Focal-Onset Seizure, Neurological Disorder
Aziende Chimiche Riunite Angelini Francesco S.p.A
Observational
936
Bari, Catanzaro, Pozzilli, Pavia, Roma, Torino, Conegliano, Udine
2023-01-24
Recruiting
Istituto Oncologico Veneto IRCCS
Observational
150
Brixen, Abano Terme, Dolo, Bassano del Grappa, Mestre, Padova, Trieste, Udine
2023-01-23
Active, closed
Daiichi Sankyo
Phase 3
1,170
Candiolo, Lucca, Orbassano, Rome, Udine, Varese, Verona
2023-01-11
Active, closed
Bristol-Myers Squibb
Phase 3
606
Meldola, Milan, Rozzano, Bologna, Catanzaro, Lecce, Pisa, Udine
2023-01-10
Recruiting
GBG Forschungs GmbH
Phase 2
170
Alessandria, Ancona, Carpi, Lecco, Legnago, Milan, Pavia, Udine
2023-01-02
Active, closed
Celcuity Inc
Phase 3
701
Milan, Modena, Monza, Parma, Prato, Rome, Udine
2022-12-08
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Chieti, Bari, Catanzaro, Naples, Udine, Rome, Genoa, Bergamo
2022-11-21
Active, closed
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
NCT07232953Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
DrugsTreosulfan·Fludarabine
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2
82
Reggio Calabria, Naples, Modena, Udine, Brescia, Milan, Cuneo, Ancona
2022-11-10
Recruiting
Regeneron Pharmaceuticals
Observational
500
Misterbianco, Florence, Udine, Rozzano, Orbassano, Pisa, Catania, Milan
2022-10-26
Recruiting
University of Milano Bicocca
Observational
500
Bari, Bologna, Brescia, Catania, Naples, Roma, Torino, Udine
2022-09-08
Recruiting
ModernaTX, Inc.
Phase 1/2
361
Udine
2022-09-01
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Ancona, Milan, Salerno, Udine, Naples
2022-08-04
Active, closed
Denali Therapeutics Inc.
Phase 2/3
65
Udine
2022-07-21
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Pavia, Udine
2022-07-14
Active, closed
Genentech, Inc.
Observational
400
Udine, Rome, Milan
2022-05-27
Recruiting
Type 2 Diabetes, Obesity and Cortisol Excess
NCT05759637Diabetes Mellitus, Type 2, Obesity, Cortisol; Hypersecretion
Istituto Auxologico Italiano
Observational
3,200
Milan, Roma, Siena, Udine
2022-05-06
Active, closed
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
MaaT Pharma
Phase 3
66
Ancona, Bologna, Genova, Milan, Reggio Calabria, Roma, Torino, Udine
2022-03-25
Active, closed
Eli Lilly and Company
Phase 3
368
Misterbianco, Meldola, Udine, Bari, Grosseto, Milan, Viterbo
2022-03-11
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
Catania, Florence, Milan, Roma, Udine
2022-01-15
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Cona, Milan, Naples, Rome, Negrar, Bari, Chieti, Udine
2022-01-13
Active, closed
Sophia Genetics SAS
Observational
4,000
Parma, Roma, Udine
2021-08-21
Active, closed
Bristol-Myers Squibb
Phase 3
670
Genova, Pavia, Udine, Verona
2021-07-13
Active, closed
EMN Trial Office S.r.l. Impresa Sociale
Phase 2
50
Bari, Milan, Perugia, Roma, Trieste, Udine
2021-03-21
Recruiting
Sentinel Node Biopsy in Endometrial Cancer
NCT04073706Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery
Queensland Centre for Gynaecological Cancer
Phase 3
760
Udine
2021-01-18
Active, closed
Pfizer
Phase 3
257
Udine, Milan, San Sisto, Roma, Rome, Siena, Candiolo, Bari
2021-01-15
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Udine, Brescia, Florence, Foggia, Meldola, Milan, Pavia, Ravenna
2020-09-16
Active, closed
Medtronic
Observational
2,200
Bologna, Cosenza, Lecce, Milan, Taranto, Udine
2020-08-01
Active, closed
Medtronic
Observational
2,200
Bologna, Castrovillari, Lecce, Milan, Taranto, Udine
2020-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Torrette, Rome, Rozzano, Florence, Lecce, Milan, Modena, Udine
2020-07-06
Recruiting
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
Memorial Sloan Kettering Cancer Center
Observational
1,715
Ferrera, Udine
2020-02-26
Active, closed
Balt Extrusion
Observational
234
Milan, Monza, Treviso, Udine
2019-11-04
Active, closed
Novo Nordisk A/S
Phase 3
134
Florence, Castelfranco Veneto, Milan, Udine, Verona
2019-10-21
Active, closed
OncoVerity, Inc.
Phase 2
103
Bologna, Brescia, Meldola, Milan, Naples, Udine
2019-07-29
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
271
Bergamo, Naples, Padova, Roma, Siena, Turin, Udine
2018-10-30
Active, closed
Medtronic
Observational
1,092
Bologna, Castrovillari, Lecce, Milan, Taranto, Udine
2017-08-21
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
518
Bologna, Cona, Milan, Segrate, Udine
2017-06-21
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
DrugIbrutinib
Pharmacyclics Switzerland GmbH
Phase 4
297
Milan, Padova, Pavia, Torino, Udine
2017-05-22
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
Infectopharm Arzneimittel GmbH
Observational
1,000
Bari, Cuneo, Genova, Milan, Palermo, Rome, Torino, Udine
2016-12
Recruiting
Boston Scientific Corporation
Observational
300
Ferrara, Mestre, Rome, Udine
2016-03-07
Recruiting
Boston Scientific Corporation
Observational
1,500
Arcugnano, Ferrara, Mestre, Milan, Pavia, Rome, Udine
2014-03-04
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Alexion Pharmaceuticals, Inc.
Observational
300
Bari, Naples, Udine, Genoa, Bergamo, Milan, Turin, Florence
2013-05-30
Active, closed
Genentech, Inc.
Phase 2
378
Potenza, Catanzaro, Naples, Meldola, Parma, Aviano (PN), Udine, Milan
2008-10-16
Rows per page Showing 1–123 of 123
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-italy/city/udine

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,791 studies in total at the last sync on 11 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 123 of those studies with a site in Udine.

How many clinical trials are recruiting in Udine?

65 of the 123 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 51 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Udine), 123 studies
PhaseStudiesRecruitingShare
Phase 3401532.5%
Observational372530.1%
Phase 220916.3%
Not applicable1178.9%
Phase 2/3624.9%
Phase 4544.1%
Phase 1/2322.4%
Phase 1110.8%

Most active sponsors

Lead sponsors with the most studies (Udine)
Lead sponsorStudiesRecruiting
University of Udine54
Bristol-Myers Squibb40
Janssen Research & Development, LLC43
Merck Sharp & Dohme LLC42
Novo Nordisk A/S43
AstraZeneca31
Boston Scientific Corporation32
European Organisation for Research and Treatment of Cancer - EORTC30
Medtronic30
University of Milano Bicocca33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.